Biosion bispecific antibody therapies to be featured at the American Association for Cancer Research (AACR) annual meeting 2023

NEWARK,Del.,March 22,2023 -- Biosion USA,Inc. (Biosion),a global R&D biotechnology company,today announced the upcoming presentations of non-clinical data from its oncology pipeline,includingBSI-507: anti-PD1ⅹanti-PVRIG bispecific antibodyand BSI-508: anti-PD1ⅹanti-CD47 bispecific antibody,at the American Association for Cancer Research (AACR) Annual Meeting to be held from April 14 to 19,2023.

BSI-507,a First-in-Class Bispecific Antibody Targeting PD1 and PVRIG for Cancer Immunotherapy

BSI-507,a first-in-class anti-PD1ⅹanti-PVRIG bispecific antibody,discovered through Biosion's H³antibody discovery platform,is able toblock both PD-1 and PVRIG pathways to enhance reversal of T cell inhibition. BSI-507 demonstrates favorable biophysical and functional characteristics,supporting the initiation of development activities including manufacturing and IND-enabling studies.

More details：https://www.abstractsonline.com/pp8/#!/10828/presentation/3434

BSI-508,a Novel Bispecific Fusion Molecule Targeting PD1 and CD47 for Cancer Immunotherapy

BSI-508is a novel anti-PD1ⅹanti-CD47 bispecific fusion molecule combining both T-cell activation and macrophage mediated phagocytosis together for superior tumor killing. BSI-508 was discovered through Biosion's H³antibody discovery platform. BSI-508 demonstrates favorable biophysical and functional characteristics,supporting the initiation of development activities including manufacturing and IND-enabling studies.

More details：https://www.abstractsonline.com/pp8/#!/10828/presentation/3654

About Biosion

Biosion is a global,clinical-stage biotechnology company committed to developing antibody-based therapies to improve patient outcomes for the treatment of immune and oncologic diseases. Established in 2017,Biosion has built a pipeline of innovative biologics through its internally derived proprietary technologies including the H³ antibody discovery platform,SynTracer®high-throughput endocytosis platform,and Flexibody™ bispecific platform. Biosion's lead asset,BSI-045B (anti-TSLP mAb),is currently in phase-II for severe asthma and phase-I for atopic dermatitis. Biosion and partners have plans to progress the immune-oncology and antibody drug conjugate-based portfolio into clinical trials for oncology indications over the next year. Biosion has operations in the US,Australia,and China. To learn more about Biosion,please go towww.biosion.com